nach oben

Graefe's Archive for Clinical and Experimental Ophthalmology

Erschienen in:

01.01.2013 | Oncology

Chemosensitivity of conjunctival melanoma cell lines to target-specific chemotherapeutic agents

verfasst von: Henrike Westekemper, Michael Freistuehler, Norbert Bornfeld, Klaus-Peter Steuhl, Max Scheulen, Ralf A. Hilger

Erschienen in: Graefe's Archive for Clinical and Experimental Ophthalmology | Ausgabe 1/2013

Einloggen, um Zugang zu erhalten

Abstract

Objective

In conjunctival melanoma, local chemotherapy has been based so far on clinical evidence and limited to the therapy of melanoma in situ. Our aim was to define substances that may have the potential to add to therapeutic options in extended local growth and metastatic disease. Two conjunctival cell lines (CRMM-1 and CRMM-2) have been established from recurrent conjunctival melanoma. In this study, we examined the chemosensitivity of these cell lines to different cytotoxic substances.

Materials and methods

The cell lines CRMM-1 and CRMM-2 were exposed to chemotherapeutics for 24 h and the IC50 was generated. Sulforhodamin-B assays were used for quantification of in vitro efficacy. Time of exposure and escalating concentrations of the substances were adapted to the experimental setting.

Results

Bortezomib, clusianone 502 (nemorosone), ranpirnase, and sorafenib were efficient in inhibiting the growth of conjunctival melanoma cell lines. The IC50 achieved concentrations below or around 10 μM for these substances.

Conclusions

Bortezomib, clusianone 502, ranpirnase, and sorafenib inhibited growth in conjunctival melanoma cell lines efficiently. The new substances may be a suitable alternative for local therapy. New therapeutic options with highly specific targeted agents for metastatic disease have to be evaluated in further experiments.

Demirci H, McCormick S, Finger P (2000) Topical mitomycin chemotherapy for conjunctival malignant melanoma and primary acquired melanosis with atypia: clinical experience with histopathologic observations. Arch Ophthalmol 118(7):885–891PubMed

Finger P, Czechonska G, Liarikos S (1998) Topical mitomycin C chemotherapy for conjunctival melanoma and PAM with atypia. Br J Ophthalmol 82:476–479PubMedCrossRef

Kurli M, Finger P (2005) Topical mitomycin chemotherapy for conjunctival malignant melanoma and primary acquired melanosis with atypia: 12 years’ experience. Graefes Arch Clin Exp Ophthalmol 243(11):1108–1114PubMedCrossRef

Folberg R, Mc Lean IW, Zimmermann LE (1985) Malignant melanoma of the conjunctiva. Hum Pathol 16:136–143PubMedCrossRef

Seregard S, Kock E (1992) Conjunctival malignant melanoma in Sweden 1969–1991. Acta Ophthalmol Scand 70:289–296

Nareyeck G, Wuestemeyer H, von der Haar D, Anastassiou G (2005) Establishment of two cell lines derived from conjunctival melanomas. Exp Eye Res 81:361–362PubMedCrossRef

Westekemper H, Freistuehler M, Anastassiou G, Nareyeck G, Bornfeld N, Steuhl K, Scheulen M, Hilger R (2012) Chemosensitivity of conjunctival melanoma cell lines to single chemotherapeutic agents and combinations. Br J Ophthalmol 96(4):591–596PubMedCrossRef

Adams J, Palombella V, Sausville E, Johnson J, Destree A, Lazarus D, Maas J, Pien C, Prakash S, Elliott P (1999) Proteasome Inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 59:2615–2622PubMed

Ludwig H, Khayat D, Giaccone G, Facon T (2005) Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies. Cancer 104:1794–1807PubMedCrossRef

10.

Montagut C, Rovira A, Albanell J (2006) The proteasome: a novel target for anticancer therapy. Clin Transl Oncol 8(5):313–317PubMedCrossRef

11.

Simons S, Scheulen M, Jaehde U (2006) Bortezomib. Dtsch Med Wochenschr 131(5):214–218PubMedCrossRef

12.

Diaz-Carballo D, Seeber S, Strumberg D, Hilger RA (2003) Novel antitumoral compound isolated from Clusia rosea. Int J Clin Pharmacol Ther 41(12):622–623PubMed

13.

Diaz-Carballo D, Malak S, Freistuhler M, Elmaagacli A, Bardenheuer W, Reusch HP (2008) Nemorosone blocks proliferation and induces apoptosis in leukemia cells. Int J Clin Pharmacol Ther 46(8):428–439PubMed

14.

Holtrup F, Bauer A, Fellenberg K, Hilger RA, Wink M, Hoheisel JD (2011) Microarray analysis of nemorosone-induced cytotoxic effects on pancreatic cancer cells reveals activation of the unfolded protein response (UPR). Br J Pharmacol 162(5):1045–1059PubMedCrossRef

15.

Lee I (2008) Ranpirnase (Onconase), a cytotoxic amphibian ribonuclease, manipulates tumour physiological parameters as a selective killer and a potential enhancer for chemotherapy and radiation in cancer therapy. Expert Opin Biol Ther 8(6):813–827PubMedCrossRef

16.

Haigis M, Kurten E, Raines R (2003) Ribonuclease inhibitor as an intracellular sentry. Nucleic Acids Res 31(3):1024–1032PubMedCrossRef

17.

Wilhelm S, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, Cao Y, Shujath J, Gawlak S, Eveleigh D, Rowley B, Liu L, Adnane L, Lynch M, Auclair D, Taylor I, Gedrich R, Voznesensky A, Riedl B, Post L, Bollag G, Trail P (2004) BAY 43–9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64:7099–7109PubMedCrossRef

18.

Carlomagno F, Anaganti S, Guida T, Salvatore G, Troncone G, Wilhelm S, Santoro M (2006) BAY 43–9006 inhibition of oncogenic RET mutants. J Natl Cancer Inst 98(5):326–334PubMedCrossRef

19.

Westekemper H, Freistuehler M, Anastassiou G, Nareyeck G, Zeschnigk M, Bornfeld N, Steuhl K, Scheulen M, Hilger R (2011) Chemosensitivity of conjunctival melanoma cell lines to chemotherapeutic agents. Int J Clin Pharmacol Ther 48(1):78–80

20.

Tschentscher F, Prescher G, Zeschnigk M, Horsthemke B, Lohmann DR (2000) Identification of chromosomes 3, 6, and 8 aberrations in uveal melanoma by microsatellite analysis in comparison to comparative genomic hybridization. Cancer Genet Cytogenet 122(1):13–17PubMedCrossRef

21.

Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren J, Bokesch H, Kenney S, Boyd M (1990) New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 82(13):1107–1112PubMedCrossRef

22.

Wang W, Abbruzzese J, Evans D, Larry L, Cleary K, Chiao P (1999) The nuclear factor-kappa B RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells. Clin Cancer Res 5:119–127PubMed

23.

Duffey D, Chen Z, Dong G, Ondrey F, Nejad-Sattari M, Dong G, Van Waes C (1999) Expression of a dominant-negative mutant inhibitor-kappaBalpha of nuclear factor-kappaB in human head and neck squamous cell carcinoma inhibits survival, proinflammatory cytokine expression, and tumor growth in vivo. Cancer Res 59:3468–3474PubMed

24.

Shattuck-Brandt R, Richmond A (1997) Enhanced degradation of I-kappaB alpha contributes to endogenous activation of NF-kappaB in Hs294T melanoma cells. Cancer Res 57:3032–3039PubMed

25.

Dhawan P, Richmond A (2002) A novel NF-kappa B-inducing kinase-MAPK signaling pathway up-regulates NF-kappa B activity in melanoma cells. J Biol Chem 277:7920–7928PubMedCrossRef

26.

Yang J, Richmond A (2001) Constitutive kappaB kinase activity correlates with nuclear factor-kappaB activation in human melanoma cells. Cancer Res 61:4901–4909PubMed

27.

Nyormoi O, Bar-Eli M (2003) Transcriptional regulation of metastasis-related genes in human melanoma. Clin Exp Metastasis 20:251–263PubMedCrossRef

28.

Ivanov V, Bhoumik A, Ronai Z (2003) Death receptors and melanoma resistance to apoptosis. Oncogene 22:3152–3161PubMedCrossRef

29.

Amiri K, Horton L, LaFleur B, Sosman J, Richmond A (2004) Augmenting chemosensitivity of malignant melanoma tumors via proteasome inhibition: implication for bortezomib (VELCADE, PS-341) as a therapeutic agent for malignant melanoma. Cancer Res 64:4912–4918PubMedCrossRef

30.

Arnold U, Schulenburg C, Schmidt D, Ulbrich-Hofmann R (2006) Contribution of structural peculiarities of onconase to its high stability and folding kinetics. Biochemistry 45:3580–3587PubMedCrossRef

31.

Leland P, Schultz L, Kim B, Raines R (1998) Ribonuclease A variants with potent cytotoxic activity. Proc Natl Acad Sci U S A 95:10407–10412PubMedCrossRef

32.

Arnold U, Ulbrich-Hofmann R (2006) Natural and engineered ribonucleases as potential cancer therapeutics. Biotechnol Lett 28:1615–1622PubMedCrossRef

33.

Benito A, Ribo M, Vilanova M (2005) On the track of antitumour ribonucleases. Mol Biosyst 1:294–302PubMedCrossRef

34.

Pavlakis N, Vogelzang N (2006) Ranpirnase—an antitumour ribonuclease: its potential role in malignant mesothelioma. Expert Opin Biol Ther 6:391–399PubMedCrossRef

35.

Egberts F, Kahler K, Livingstone E, Hauschild A (2008) Metastatic melanoma: scientific rationale for sorafenib treatment and clinical results. Onkologie 31(7):398–403PubMedCrossRef

36.

McDermott D, Sosman J, Gonzalez R, Hodi F, Linette G, Richards J, Jakub J, Beeram M, Tarantolo S, Agarwala S, Frenette G, Puzanov I, Cranmer L, Lewis K, Kirkwood J, White J, Xia H, Patel K, Hersh E (2008) Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group. J Clin Oncol 1(26):2178–2185CrossRef

37.

Panka DJ, Wang W, Atkins MB, Mier JW (2006) The Raf inhibitor BAY 43–9006 (Sorafenib) induces caspase-independent apoptosis in melanoma cells. Cancer Res 66(3):1611–1619PubMedCrossRef

38.

Fecher L, Amaravadi R, Flaherty K (2008) The MAPK pathway in melanoma. Curr Opin Oncol 20(2):183–189PubMedCrossRef

Titel: Chemosensitivity of conjunctival melanoma cell lines to target-specific chemotherapeutic agents
verfasst von: Henrike Westekemper
Michael Freistuehler
Norbert Bornfeld
Klaus-Peter Steuhl
Max Scheulen
Ralf A. Hilger
Publikationsdatum: 01.01.2013
Verlag: Springer-Verlag
Erschienen in: Graefe's Archive for Clinical and Experimental Ophthalmology / Ausgabe 1/2013
Print ISSN: 0721-832X
Elektronische ISSN: 1435-702X
DOI: https://doi.org/10.1007/s00417-012-2083-8

Neu im Fachgebiet Augenheilkunde

Metastase in der periokulären Region

Metastasen Leitthema

Orbitale und periokuläre metastatische Tumoren galten früher als sehr selten. Aber mit der ständigen Aktualisierung von Medikamenten und Nachweismethoden für die Krebsbehandlung werden neue Chemotherapien und Strahlenbehandlungen eingesetzt. Die …

Staging und Systemtherapie bei okulären und periokulären Metastasen

Metastasen Leitthema

Metastasen bösartiger Erkrankungen sind die häufigsten Tumoren, die im Auge diagnostiziert werden. Sie treten bei ungefähr 5–10 % der Patienten mit soliden Tumoren im Verlauf der Erkrankung auf. Besonders häufig sind diese beim Mammakarzinom und …

Wundheilung nach Trabekulektomie

Trabekulektomie CME-Artikel

Die überschießende Wundheilung in der filtrierenden Glaukomchirurgie ist ein zentraler Faktor für ein operatives Versagen. Nach der Einführung der Trabekulektomie in den 1960er-Jahren wurden viele Faktoren erkannt, die mit einer vermehrten …

„standard operating procedures“ (SOP) – Vorschlag zum therapeutischen Management bei periokulären sowie intraokulären Metastasen

Metastasen Leitthema

Peri- sowie intraokuläre Metastasen sind insgesamt gesehen selten und meist Zeichen einer fortgeschrittenen primären Tumorerkrankung. Die Therapie ist daher zumeist palliativ und selten kurativ. Zudem ist die Therapiefindung sehr individuell. Die …

Update Augenheilkunde

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Chemosensitivity of conjunctival melanoma cell lines to target-specific chemotherapeutic agents

Abstract

Objective

Materials and methods

Results

Conclusions

Neu im Fachgebiet Augenheilkunde

Metastase in der periokulären Region

Staging und Systemtherapie bei okulären und periokulären Metastasen

Wundheilung nach Trabekulektomie

„standard operating procedures“ (SOP) – Vorschlag zum therapeutischen Management bei periokulären sowie intraokulären Metastasen

Update Augenheilkunde

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Objective

Materials and methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2013

Decreased retinal sensitivity and loss of retinal nerve fibers in multiple system atrophy

Gamma-knife-based stereotactic radiosurgery for medium- and large-sized posterior uveal melanoma

Treatment of upper eyelid retraction related to thyroid-associated ophthalmopathy using subconjunctival triamcinolone injections

Femtosecond lenticule extraction (ReLEx®) for correction of hyperopia — first results

Physiological evidence for impairment in autosomal dominant optic atrophy at the pre-ganglion level

Reply to the letter by Zhang and Hoffman: Comments on corneal intrastromal tissue modeling with the femtosecond laser

Neu im Fachgebiet Augenheilkunde

Metastase in der periokulären Region

Staging und Systemtherapie bei okulären und periokulären Metastasen

Wundheilung nach Trabekulektomie

„standard operating procedures“ (SOP) – Vorschlag zum therapeutischen Management bei periokulären sowie intraokulären Metastasen

Update Augenheilkunde